{"id":154809,"date":"2026-11-19T12:17:48","date_gmt":"2026-11-19T03:17:48","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4575-20261119-01_wp_earnings_guidance\/"},"modified":"2026-11-19T12:17:48","modified_gmt":"2026-11-19T03:17:48","slug":"4575-20261119-01_wp_earnings_guidance","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/","title":{"rendered":"Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501"},"content":{"rendered":"<p>Received approval to commence the European Phase 3 clinical trial for CBP501. The trial targets third-line pancreatic cancer; the primary endpoint is overall survival. The trial is planned in about 50 sites across 8 countries. No earnings guidance for the current fiscal year is disclosed; the company will disclose information as progress is made.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4575","jir_company_name":"CanBas Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4575-20261119-01.pdf","jir_short_summary":"Received approval to commence the European Phase 3 clinical trial for CBP501. The trial targets third-line pancreatic cancer; the primary endpoint is overall survival. The trial is planned in about 50 sites across 8 countries. No earnings guidance for the current fiscal year is disclosed; the company will disclose information as progress is made.","jir_summary":"### Clinical Development Progress\nCanBas Co., Ltd. announced that it obtained approval to commence the European Phase 3 clinical trial of CBP501. The trial is a randomized, open-label, multicenter study targeting third-line treatment for pancreatic cancer. The primary endpoint is overall survival (OS). The treatment arm will receive a triple combination of CBP501 + cisplatin + nivolumab, while the control arm will receive the best four regimens selected by investigators. The study is designed for approximately 180 patients across two arms, planned at about 50 sites in 8 countries. An interim analysis will be conducted when 25% of the data required for the final analysis have been collected. Preparations for trial initiation and contract signings are proceeding sequentially.\n\n### Earnings Outlook and Future Disclosure\nBecause the Phase 3 trial has the character of a pivotal study, there are strict constraints on data disclosure during the trial period. It is difficult to reasonably predict the impact of commencing this trial on the current fiscal year\u2019s results, and therefore the company is not disclosing earnings guidance at this time. The company will timely disclose any impacts or outlook related to trial preparations and initiation as progress is made.","jir_financial_highlights":"Earnings Guidance: Unknown (Not disclosed)","jir_category":"","jir_hashtags":"#CBP501, #EuropeanPhase3Trial, #ImmuneIgniter","jir_key_figures":"Approval to commence Phase 3 clinical trial\nIndication: pancreatic cancer third-line treatment\nTrial size: approx. 180 people (total for 2 arms)","jir_meta_title":"CanBas Co., Ltd. \u2014 Approval to Start European Phase 3 Trial for CBP501 | Unclear Impact on FY2027","jir_meta_description":"Announcement of approval to commence the European Phase 3 clinical trial for CBP501. The trial targets third-line pancreatic cancer with overall survival as the primary endpoint. Earnings guidance is not disclosed and may be updated depending on future progress.","jir_og_title":"Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501","jir_og_description":"CanBas Co., Ltd. received approval to start the European Phase 3 clinical trial for CBP501; trial overview and future disclosure policy are provided. Earnings guidance is not disclosed at this time.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58229,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-154809","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501 - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/\",\"name\":\"Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501 - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-19T03:17:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501 - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/","url":"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/","name":"Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501 - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-19T03:17:48+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4575\/ir\/4575-20261119-01_wp_earnings_guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"58229","title":"CANBAS CO LTD","ticker":"4575"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=154809"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154809\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=154809"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=154809"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=154809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}